Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 301–400 of 1,002
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Wu, X., Yang, X., Xiong, Y., Li, R., Ito, T., Ahmed, T. A., Karoulia, Z., Adamopoulos, C., Wang, H., Wang, L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00174-z · Cited by 84
Bagegni, N. A., Thomas, S. N., Liu, N., Luo, J. R., Hoog, J., Northfelt, D., Goetz, M. P., Forero, A., Bergqvist, M., Karén, J., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0913-7 · Cited by 78
Shee, K., Yang, W., Hinds, J. W., Hampsch, R. A., Varn, F. S., Traphagen, N. A., Patel, K., Cheng, C., Jenkins, N. P., Kettenbach, A. N., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171818 · Cited by 73
“CDK4/6 inhibition with palbociclib, which is approved for the treatment of advanced ER+ breast cancer in combination with anti-estrogens (Turner et al., 2015; Finn et al., 2016), abrogated FGF2-mediated rescue from anti-estrogens, PI3Ki, and mTORC1i (Figs.”
BackgroundMills, M. N., Figura, N. B., Arrington, J. A., Yu, H.-H. M., Etame, A. B., Vogelbaum, M. A., Soliman, H. H., Czerniecki, B. J., Forsyth, P. A., Han, H. S., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05552-2 · Cited by 81
Mukai, H., Shimizu, C., Masuda, N., Ohtani, S., Ohno, S., Takahashi, M., Yamamoto, Y., Nishimura, R., Sato, N., Ohsumi, S., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1353-9 · Cited by 75
Self-citationVarella, L., Eziokwu, A. S., Jia, X., Kruse, M. L., Moore, H. C. F., Budd, G. T., Abraham, J., & Montero, A. J. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05176-1 · Cited by 77
Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., et al. (2024) · Future Oncology · doi:10.2217/fon-2023-0188 · Cited by 72
Self-citationMasuda, J., Sakai, H., Tsurutani, J., Tanabe, Y., Masuda, N., Iwasa, T., Takahashi, M., Futamura, M., Matsumoto, K., Aogi, K., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007126 · Cited by 76
Patel, P. M., Tsiperson, V., Gottesman, S. R. S., Somma, J., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0602 · Cited by 77
“Letrozole (hereafter LET) in combination with PD is currently a first-line therapy for women with metastatic ERþ breast cancer (31).”
BackgroundGao, A., Sun, T., Ma, G., Cao, J., Hu, Q., Chen, L., Wang, Y., Wang, Q., Sun, J., Wu, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06309-8 · Cited by 75
Potter, B. V. L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0045 · Cited by 73
Boers, J., Venema, C. M., de Vries, E. F. J., Glaudemans, A. W. J. M., Kwee, T. C., Schuuring, E. M. D., Martens, J. W. M., Elias, S. G., Hospers, G. A. P., & Schroder, C. P. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.024 · Cited by 73
Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
Li, Z., Zou, W., Zhang, J., Zhang, Y., Xu, Q., Li, S., & Chen, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580251 · Cited by 83
CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
Vinciguerra, G. L. R., Sonego, M., Segatto, I., Dall’Acqua, A., Vecchione, A. M., Baldassarre, G., & Belletti, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891580 · Cited by 81
“(NCT01740427) longer PFS respect to Letrozole alone (7)”
BackgroundTeh, J. L. F., Cheng, P. F., Purwin, T. J., Nikbakht, N., Patel, P., Chervoneva, I., Ertel, A., Fortina, P. M., Kleiber, I., HooKim, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0699 · Cited by 75
“1E), consistent with toxicities seen in preclinical and clinical studies (10).”
Shimoi, T., Nagai, S. E., Yoshinami, T., Takahashi, M., Arioka, H., Ishihara, M., Kikawa, Y., Koizumi, K., Kondo, N., Sagara, Y., et al. (2020) · Breast Cancer · doi:10.1007/s12282-020-01085-0 · Cited by 75
The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
Luo, J., Zou, H., Guo, Y., Tong, T., Chen, Y., Xiao, Y., Pan, Y., & Li, P. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02182-5 · Cited by 97
“In addition, owing to the central role of estrogen-driven activation of CDK4/6 kinase in ER+ BC, multiple CDK4/6 kinase inhibitors, including palbociclib [55], ribociclib [56], and abemaciclib [57] have been developed for treating the advanced ER+ BC.”
BackgroundCDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
Garrido-Castro, A. C., & Goel, S. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0232-0 · Cited by 69
ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
Rozeboom, B. J., Dey, N., & De, P. K. (2019) · PubMed · Cited by 87
Pascual, J., Lim, J. S. J., Macpherson, I. R., Armstrong, A. C., Ring, A. E., Okines, A. F. C., Cutts, R. J., Herrera-Abreu, M. T., García-Murillas, I., Pearson, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0553 · Cited by 76
“Cyclin-dependent kinase-4/6 (CDK4/6) inhibitors in combination with endocrine therapy are widely approved for the treatment of advanced hormone receptor positive (HR+ve), HER2negative (HER2-ve) metastatic breast cancer, both for patients relapsing on and off adjuvant endocrine therapy (1, 2).”
BackgroundInfluentialPetroni, G., Buqué, A., Yamazaki, T., Bloy, N., Liberto, M. D., Chen‐Kiang, S., Formenti, S. C., & Galluzzi, L. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3871 · Cited by 73
“This is particularly relevant as CDK4/6 inhibitors are invariably administered to patients with metastatic ERþ breast cancer in the context of letrozole- or fulvestrant-based endocrine therapy, which appear to be required for optimal therapeutic outcomes (3, 35).”
BackgroundEmerging therapies for breast cancer
Hu, X., Huang, W., & Fan, M. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0466-3 · Cited by 67
“The study met its primary endpoint [35].”
Royce, M., Bachelot, T., Villanueva, C., Özgüroğlu, M., Azevedo, S. J., Cruz, F. M., Debled, M., Hegg, R., Toyama, T., Falkson, C. I., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0060 · Cited by 71
“53 (26) 44 (22) 38 (19) 30 (15) 35 (17)”
Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
Aggelis, V., & Johnston, S. R. D. (2019) · Drugs · doi:10.1007/s40265-019-01208-8 · Cited by 78
Bartlett, C. H., Mardekian, J., Cotter, M. J., Huang, X., Zhang, Z., Parrinello, C. M., & Bourla, A. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227256 · Cited by 72
“[13] PFS and ORR were measured per RECIST version 1.”
BackgroundMethodInfluentialRossi, V., Berchialla, P., Giannarelli, D., Nisticò, C., Ferretti, G., Gasparro, S., Russillo, M., Catania, G., Vigna, L., Mancusi, R. L., et al. (2019) · Cancers · doi:10.3390/cancers11111661 · Cited by 70
“PALOMA-2 Finn [12] 2016 III First-line therapy for MBC in patients not treated before for their metastatic disease.”
BackgroundMethodInfluentialChinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 81
“In the PALOMA-2 study (42), compared with letrozole monotherapy, letrozole combined with a CDK4/6 inhibitor (palbociclib) significantly prolonged PFS; notably, about 43% of the subjects were endocrine therapy-naive, and about 47% had received adjuvant TAM treatment.”
Falato, C., Schettini, F., Pascual, T., Brasó‐Maristany, F., & Prat, A. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102496 · Cited by 73
Palbociclib-induced autophagy and senescence in gastric cancer cells
Valenzuela, C. A., Vargas, L., Martinez, V., Bravo, S., & Brown, N. E. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.09.031 · Cited by 67
Kish, J. K., Ward, M., Garofalo, D., Ahmed, H. V., McRoy, L., Laney, J. R., Zanotti, G., Braverman, J., Yu, H., & Feinberg, B. A. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0958-2 · Cited by 70
“2%) who initiated palbociclib at 125 mg and had the dose reduced; this is partially explained by the 11% of patients who initiated treatment at doses lower than 125 mg, which was not allowed in the PALOMA-2 clinical trial [7].”
InfluentialMessina, C. G. M., Cattrini, C., Buzzatti, G., Cerbone, L., Zanardi, E., Messina, M., & Boccardo, F. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4901-0 · Cited by 74
Bardia, A., Aftimos, P. G., Bihani, T., Anderson-Villaluz, A. T., Jung, J., Conlan, M. G., & Kaklamani, V. (2019) · Future Oncology · doi:10.2217/fon-2019-0370 · Cited by 72
Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review
Assi, T., Kattan, J. G., Rassy, E., Nassereddine, H., Farhat, F., Honoré, C., Cesne, A. L., Adam, J., & Mir, O. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103029 · Cited by 74
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022) · Molecules · doi:10.3390/molecules27248828 · Cited by 75
“The selective CDK4/6 inhibitor Palbociclib was approved by the FDA for the treatment of ER-positive and HER2-negative advanced breast cancer patients [71].”
BackgroundPrecision medicine in breast cancer: reality or utopia?
Bettaïeb, A., Paul, C., Plenchette, S., Shan, J., Chouchane, L., & Ghiringhelli, F. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1239-z · Cited by 79
Müller, V., Nabieva, N., Häberle, L., Taran, F., Hartkopf, A. D., Volz, B., Overkamp, F., Brandl, A. L., Kolberg, H., Hadji, P., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.08.008 · Cited by 69
Hortobágyi, G. N. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1050-7 · Cited by 69
Figura, N. B., Potluri, T. K., Mohammadi, H., Oliver, D. E., Arrington, J. A., Robinson, T. J., Etame, A. B., Tran, N., Liu, J. K., Soliman, H. H., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03260-6 · Cited by 71
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
Scheidemann, E. R., & Shajahan‐Haq, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212292 · Cited by 74
“Within 2 years of beginning treatment in the PALOMA-2 trial, over 30% of enrolled patients developed resistance to palbociclib [26].”
BackgroundPapadimitriou, M., Pazaiti, A., Iliakopoulos, K., Markouli, M., Michalaki, V., & PAPADIMITRIOU, C. A. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119346 · Cited by 78
Rugo, H. S., Layman, R. M., Lynce, F. C., Liu, X., Li, B., McRoy, L., Cohen, A. B., Estévez, M., Curigliano, G., & Brufsky, A. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104103 · Cited by 72
Self-citationLiu, C., Lau, K.-Y., Hsu, C., Chen, J.-L., Lee, C.-H., Huang, T., Chen, Y., Huang, C.-T., Lin, P., & Tseng, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189007 · Cited by 71
Blee, A. M., He, Y., Yang, Y., Ye, Z., Yan, Y., Pan, Y., Ma, T., Dugdale, J. A., Kuehn, E., Kohli, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0653 · Cited by 74
Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began
Meisel, J. L., Venur, V. A., Gnant, M., & Carey, L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201037 · Cited by 78
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
Ulm, M. A., Ramesh, A. V., McNamara, K. M., Ponnusamy, S., Sasano, H., & Narayanan, R. (2019) · Endocrine Connections · doi:10.1530/ec-18-0425 · Cited by 73
Cardiac arrhythmia considerations of hormone cancer therapies
Barber, M., Nguyen, L. S., Wassermann, J., Spano, J., Funck‐Brentano, C., & Salem, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz020 · Cited by 69
Advances in medical treatment of breast cancer in 2022
Zhai, J., Wu, Y., Ma, F., Kaklamani, V., & Xu, B. (2023) · Cancer Innovation · doi:10.1002/cai2.46 · Cited by 76
“The PALOMA ‐ 2 trial showed that palbociclib plus letrozole can significantly improve PFS compared with placebo plus letrozole in the first ‐ line treatment of ER ‐ positive, HER2 ‐ negative advanced breast cancer (median: 24.8 vs. 14.5 months) [69].”
InfluentialO'Sullivan, C. C., Clarke, R. C., Goetz, M. P., & Robertson, J. F. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.2000 · Cited by 75
Terada, M., Ito, A., Kikawa, Y., Koizumi, K., Naito, Y., Shimoi, T., Ishihara, M., Yamanaka, T., Ozaki, Y., Hara, F., et al. (2023) · Breast Cancer · doi:10.1007/s12282-023-01505-x · Cited by 73
Di Leo, A., O’Shaughnessy, J., Sledge, G. W., Martin, M., Lin, Y., Frenzel, M., Hardebeck, M. C., Smith, I. C., Llombart-Cussac, A., Goetz, M. P., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0094-2 · Cited by 66
Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Hu, Y., Gao, J., Wang, M., & Li, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s310649 · Cited by 71
“agent for postmenopausal women with breast cancer) compared with letrozole alone.(40,41,44) Palbociclib or abemaciclib in combination with fulvestrant as a second-line treatment substantially extended progression-free survival in breast cancer patients with progression after treatment with aromatase inhibitors.”
ResultResistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
Asciolla, J. J., Wu, X., Adamopoulos, C., Gavathiotis, E., & Poulikakos, P. I. (2025) · Nature Cancer · doi:10.1038/s43018-024-00893-z · Cited by 73
“When combined with hormonal therapy, palbociclib significantly improved progression-free survival (PFS) of patients with ER + metastatic breast cancer 40,46 , resulting in approval by the FDA.”
Olaparib for the treatment of breast cancer
Griguolo, G., Dieci, M. V., Guarneri, V., & Conte, P. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1458613 · Cited by 72
van Ommen‐Nijhof, A., Konings, I. R. H. M., van Zeijl, C. J. J., Groot, C. A. U., van der Noort, V., Jager, A., & Sonke, G. S. (2018) · BMC Cancer · doi:10.1186/s12885-018-4978-1 · Cited by 70
Caparica, R., Lambertini, M., Ponde, N. F., Fumagalli, D., de Azambuja, E., & Piccart, M. J. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919827714 · Cited by 71
Chowdhary, M., Sen, N., Chowdhary, A., Usha, L., Cobleigh, M., Wang, D., Patel, K. R., Barry, P. N., & Rao, R. D. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2019.03.011 · Cited by 69
“The median time interval from blood draw and RT was 12 days (0-40) and 8 days (1-47) for pre- and postvalues, respectively.”
BackgroundSignal Transduction in Diffuse Intrinsic Pontine Glioma
Duchatel, R. J., Jackson, E. R., Alvaro, F., Nixon, B., Hondermarck, H., & Dun, M. D. (2019) · PROTEOMICS · doi:10.1002/pmic.201800479 · Cited by 70
CDK6 Inhibition: A Novel Approach in AML Management
Uras, I. Z., Sexl, V., & Kollmann, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072528 · Cited by 78
Combinatorial drug therapy in cancer - New insights
Bhatia, K. S., Bhumika, & Das, A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118134 · Cited by 75
Finn, R. S., Rugo, H. S., Gelmon, K. A., Cristofanilli, M., Colleoni, M. A., Loi, S., Schnell, P., Lu, D. R., Theall, K. P., Mori, A., et al. (2021) · The Oncologist · doi:10.1002/onco.13684 · Cited by 68
Self-citationCDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway
Fukasawa, K., Kadota, T., Horie, T., Tokumura, K., Terada, R., Kitaguchi, Y., Park, G., Ochiai, S., Iwahashi, S., Okayama, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01745-1 · Cited by 66
Rej, R. K., Roy, J., & Allu, S. R. (2024) · Cancers · doi:10.3390/cancers16030552 · Cited by 71
“…SERCAs, and PROTACs that target ER (Figure 2, Table 1). first-line or fulvestrant as a second-line ET, after progression or relapse on an AI [22–24]. approval of fulvestrant and elacestrant represent significant advancements as pure ER antagonist drugs and led the discovery of a new class…”
BackgroundBalermpas, P., Stera, S., von der Grün, J., Loutfi-Krauß, B., Forster, M.-T., Wagner, M., Keller, C., Rödel, C. M., Seifert, V., Blanck, O., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198692 · Cited by 65
Updates in the Evaluation and Management of Breast Cancer
O'Sullivan, C. C., Loprinzi, C. L., & Haddad, T. C. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.03.025 · Cited by 76
Progress in targeted therapy for breast cancer
Ju, J., Zhu, A., & Yuan, P. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2018.04.002 · Cited by 68
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
Purba, T. S., Ng’andu, K., Brunken, L., Smart, E., Mitchell, E., Hassan, N. M. K. N., O'Brien, A., Mellor, C. E. L., Jackson, J., Shahmalak, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911031 · Cited by 66
“Systemic palbociclib therapy to treat hormone receptor-positive HER2-negative breast cancer (once daily for weeks) has unsurpris-ingly been found to cause hair loss (Ro et al , 2015; Finn et al , 2016).”
The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, C. G. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0651-4 · Cited by 68
Epigenetic Therapies and Biomarkers in Breast Cancer
Brown, L. J., Achinger-Kawecka, J., Portman, N., Clark, S. J., Stirzaker, C., & Lim, E. (2022) · Cancers · doi:10.3390/cancers14030474 · Cited by 68
Bellet, M., Ahmad, F., Villanueva-Vázquez, R., Valdivia, C., Palomino-Doza, J., Ruiz, A. I., González, X., Adrover, E., Azaro, A., Valls-Margarit, M., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919833867 · Cited by 68
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Horr, C., & Buechler, S. A. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00345-2 · Cited by 69
Bardia, A., & Hurvitz, S. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0162 · Cited by 63
“8months in PALOMA-2 (13), the addition of ribociclib to letrozole increased median PFS from 16.”
BackgroundInfluentialBattisti, N. M. L., de Glas, N. A., Sedrak, M. S., Loh, K. P., Liposits, G. I., Soto‐Pérez‐de‐Celis, E., Krok‐Schoen, J. L., Menjak, I. B., & Ring, A. E. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918809610 · Cited by 65
Sun, W., Zhang, Q., Wang, R., Yang, L., Sun, Y., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648687 · Cited by 71
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, A. N., & Cristofanilli, M. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0443-7 · Cited by 71
Arnedos, M., Bayar, M. A., Cheaib, B., Scott, V., Bouakka, I., Valent, A., Adam, J., Leroux-Kozal, V., Marty, V., Rapinat, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy202 · Cited by 64
Hartkopf, A. D., Huober, J., Volz, B., Nabieva, N., Taran, F., Schwitulla, J., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.10.002 · Cited by 61
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review
Husna, S. M. N., Tan, H. T., Mohamud, R., Dyhl-Polk, A., & Wong, K. K. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918808509 · Cited by 71
The therapeutic landscape of hepatocellular carcinoma
Gallage, S., Beccaria, M. G., Szydlowska, M., Rahbari, M., Mohr, R. U., Tacke, F., & Heikenwälder, M. F. (2021) · Med · doi:10.1016/j.medj.2021.03.002 · Cited by 64
Fradley, M. G., Nguyen, N., Madnick, D. L., Chen, Y., DeMichele, A. M., Makhlin, I., Dent, S. F., Lefebvre, B., Carver, J. R., Upshaw, J. N., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029361 · Cited by 63
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Kudo, R., Safonov, A. M., Jones, C., Moiso, E., Dry, J. R., Shao, H., Nag, S., da Silva, E. M., Yildirim, S. Y., Li, Q., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.009 · Cited by 75
“However, there is high variance in the degree and duration of benefit from these therapies ranging from a few months to over 5 years (12-14).”
Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer
O'Shaughnessy, J., Thaddeus Beck, J., & Royce, M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.013 · Cited by 57
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 62
“Subsequent larger phase III trials have not only confirmed these results (7, 39, 40), but also extended the proof of principle of synergy in combining other CDK4/6 inhibitors with the selective ER degrader, fulvestrant (41, 42), or the antiestrogen, tamoxifen (40, 43).”
BackgroundMcCartney, A., Bonechi, M., Luca, F. D., Biagioni, C., Curigliano, G., Moretti, E., Minisini, A. M., Bergqvist, M., Benelli, M., Migliaccio, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3271 · Cited by 62
“PFS analyses of patients randomized to receive palbociclib and letrozole as a part of PALOMA-2 revealed 49 censored observations made by investigators within the first 3 months of the trial, increasing to 60 at central assessment (1).”
MethodWest, M. T., Smith, C. E. P., Kaempf, A. J., Kohs, T. C. L., Amirsoltani, R., Ribkoff, J., Choung, J., Palumbo, A., Mitri, Z. I., & Shatzel, J. J. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13590 · Cited by 61
CDK4/6 inhibition in early and metastatic breast cancer: A review
de Groot, A. F., Kuijpers, C. C. H. J., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.003 · Cited by 73
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, S., Sami, A., Manna, M., Pauls, M., & Ahmed, S. (2021) · Current Oncology · doi:10.3390/curroncol28030168 · Cited by 67
“Parameters PALOMA-1/TRIO-18 [62,63] PALOMA-2 [64] MONALEESA-2 [65] MONALEESA-7 [68,69] MONARCH-3 [66,67]”
InfluentialMasuda, N., Inoue, K., Nakamura, R., Rai, Y., Mukai, H., Ohno, S., Hara, F., Mori, Y., Hashigaki, S., Muramatsu, Y., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1359-3 · Cited by 61
Martin, J., Handorf, E. A., Montero, A. J., & Goldstein, L. J. (2022) · The Oncologist · doi:10.1093/oncolo/oyac075 · Cited by 67
Luo, L., Yang, P., Mastoraki, S., Rao, X., Wang, Y., Kettner, N. M., Raghavendra, A. S., Tripathy, D., Damodaran, S., Hunt, K. K., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02226-9 · Cited by 70
Ippolito, E., Greco, C., Silipigni, S., Dell’Aquila, E., Petrianni, G. M., Tonini, G., Fiore, M., D’Angelillo, R. M., & Ramella, S. (2019) · The Breast · doi:10.1016/j.breast.2019.05.001 · Cited by 61
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 62
Wu, H., & Chu, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020636 · Cited by 64
Re, M. D., Omarini, C., Diodati, L., Palleschi, M., Meattini, I., Crucitta, S., Lorenzini, G., Isca, C., Fontana, A., Livi, L., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100231 · Cited by 63
“Palbociclib demonstrated clinical efficacy in combination with fulvestrant or aromatase inhibitors as first- or secondline treatment of premenopausal and postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) patients.(13,14) Palbociclib is a…”
BackgroundPalmbos, P. L., Daignault‐Newton, S., Tomlins, S. A., Agarwal, N., Twardowski, P. W., Morgans, A. K., Kelly, W. K., Arora, V. K., Antonarakis, E. S., Siddiqui, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0024 · Cited by 61
“Palbociclib is a highly selective reversible inhibitor of CDK 4 and 6 which has been shown to significantly improve progression-free survival (PFS) when combined with letrazole in estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (16).”
BackgroundCDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Zhou, F. H., Downton, T. D., Freelander, A., Hurwitz, J., Caldon, C. E., & Lim, E. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1148792 · Cited by 67
“Palbociclib, ribociclib and abemaciclib have demonstrated statistically significant and clinically meaningful PFS benefit when added to ET in both the first and second-line advanced ER+/HER2breast cancer settings (Cristofanilli et al., 2016; Finn et al., 2016; Sledge et al., 2017; Hortobagyi et al., 2018; Slamon et al…”
BackgroundOrcutt, X., Chen, K., Mamtani, R., Long, Q., & Parikh, R. B. (2025) · Nature Medicine · doi:10.1038/s41591-024-03352-5 · Cited by 59
Warth, B., Raffeiner, P., Granados, A., Huan, T., Fang, M., Forsberg, E. M., Benton, H. P., Goetz, L. H., Johnson, C. H., & Siuzdak, G. E. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2017.12.010 · Cited by 66
Cook, M. M., Rabadi, L. S. A., Kaempf, A. J., Saraceni, M. M., Savin, M. A., & Mitri, Z. I. (2020) · The Oncologist · doi:10.1002/onco.13609 · Cited by 59
PARP14 regulates cyclin D1 expression to promote cell-cycle progression
O’Connor, M. J., Thakar, T., Nicolae, C. M., & Moldovan, G. (2021) · Oncogene · doi:10.1038/s41388-021-01881-8 · Cited by 62
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.